Carlos Restrepo - Adicet Bio Senior Vice President - Performance Chemicals
| ACET Stock | USD 2.03 0.24 10.57% |
President
Mr. Carlos Restrepo is Senior Vice President Performance Chemicals of the Company. Prior to joining Aceto, he spent eighteen years at International Specialty Products, a specialty chemical manufacturer that is now part of Ashland Inc., where he most recently served as Vice President, Intermediates and Solvents. Prior to this role, Mr. Restrepo served successively as ISPs Senior Vice President General Manager, Industrial Chemicals and Elastomers and Vice President, Global Sales and Marketing, Industrial Chemicals. Earlier in his tenure at ISP, Mr. Restrepo directed its chemical businesses in Mexico and Singapore. Prior to ISP, Mr. Restrepo worked for ten years at HuntsmanTexaco Chemical and Dow Chemical in various sales, marketing and general management roles since 2014.
| Age | 53 |
| Tenure | 10 years |
| Address | 131 Dartmouth Street, Boston, MA, United States, 02116 |
| Phone | 650 503 9095 |
| Web | https://www.adicetbio.com |
Adicet Bio Management Efficiency
The company has return on total asset (ROA) of (0.308) % which means that it has lost $0.308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6169) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.67 in 2024. Liabilities And Stockholders Equity is likely to gain to about 214.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 18.3 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Trisha Coady | HealthStream | 48 | |
| Robert Aspbury | Certara | 52 | |
| Jeffrey Cunningham | HealthStream | 57 | |
| John DiBella | Simulations Plus | 35 | |
| Jill MS | Simulations Plus | 55 | |
| Lee Neumann | Agiliti | 48 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Thomas Schultz | HealthStream | 49 | |
| Michael Sousa | HealthStream | 55 | |
| Patrick PharmD | Certara | 53 | |
| Nicholas Meeks | Streamline Health Solutions | 32 | |
| Thomas Gibson | Streamline Health Solutions | 60 | |
| Robert Creviston | Agiliti | 57 | |
| Shaun Priest | Streamline Health Solutions | 46 | |
| Scott McQuigg | HealthStream | 50 | |
| Leif Pedersen | Certara | 59 | |
| Bettyann Bird | Agiliti | 63 | |
| James Pekarek | Agiliti | 55 | |
| William Garvis | Streamline Health Solutions | 50 | |
| Michael Collier | HealthStream | 48 | |
| Scott Christensen | Agiliti | 59 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.31 |
Adicet Bio Leadership Team
Elected by the shareholders, the Adicet Bio's board of directors comprises two types of representatives: Adicet Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adicet. The board's role is to monitor Adicet Bio's management team and ensure that shareholders' interests are well served. Adicet Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adicet Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesco MD, Chief VP | ||
| Edward Borkowski, CFO | ||
| Rebecca Roof, Interim CFO | ||
| Hans Noetzli, Lead Independent Director | ||
| Douglas Roth, CFO, Principal Accounting Officer, Chief Admin. Officer, Sr. VP, Treasurer and Assistant Secretary | ||
| Natasha Giordano, Director | ||
| Alan Levin, Independent Director | ||
| Daniel Yarosh, Director | ||
| Salvatore Guccione, CEO and President and Director | ||
| Albert Eilender, Chairman of the Board | ||
| BA CPA, Pres CEO | ||
| Jody Burfening, IR Contact Officer | ||
| Blake Aftab, Senior Officer | ||
| William Britton, Independent Director | ||
| Terry Kippley, Senior Vice President - Agricultural Protection Products | ||
| Amy Locke, Head Resources | ||
| Frances Scally, Chief Accounting Officer | ||
| Satish Srinivasan, President and COO of Rising Pharmaceuticals | ||
| Frank DeBenedittis, Sr. VP of Corporate Bus. Devel. and International Sr. VP of Active Pharmaceutical Ingredients | ||
| Donald Healey, Chief Officer | ||
| Richard Randall, Independent Director | ||
| Brian Harvey, Chief Officer | ||
| Carlos Restrepo, Senior Vice President - Performance Chemicals | ||
| Vimal Kavuru, President of Rising | ||
| Nicholas Shackley, Senior Vice President - Pharmaceutical Ingredients | ||
| Steven Rogers, Sr. VP, General Counsel and Corporate Secretary | ||
| Walter Kaczmarek, COO | ||
| William Kennally, Director | ||
| Charles Alaimo, Senior Vice President - Human Resources | ||
| Fran Scally, Chief Accounting Officer | ||
| Raymond Bartone, Senior Vice President - Nutritionals | ||
| Aya Jakobovits, Founder Director |
Adicet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adicet Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 27.57 M | ||||
| Shares Outstanding | 82.15 M | ||||
| Shares Owned By Insiders | 1.42 % | ||||
| Shares Owned By Institutions | 68.02 % | ||||
| Number Of Shares Shorted | 7.69 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 9.72 X |
Pair Trading with Adicet Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adicet Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adicet Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Adicet Stock
| 0.73 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
Moving against Adicet Stock
| 0.75 | ELMD | Electromed | PairCorr |
| 0.74 | HIMS | Hims Hers Health Financial Report 13th of May 2024 | PairCorr |
| 0.69 | ALC | Alcon AG Financial Report 14th of May 2024 | PairCorr |
| 0.63 | HOLX | Hologic Financial Report 6th of May 2024 | PairCorr |
| 0.52 | BAX | Baxter International Financial Report 25th of April 2024 | PairCorr |
The ability to find closely correlated positions to Adicet Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adicet Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adicet Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adicet Bio to buy it.
The correlation of Adicet Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adicet Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adicet Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adicet Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.Note that the Adicet Bio information on this page should be used as a complementary analysis to other Adicet Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Adicet Stock analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Adicet Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.62) |
The market value of Adicet Bio is measured differently than its book value, which is the value of Adicet that is recorded on the company's balance sheet. Investors also form their own opinion of Adicet Bio's value that differs from its market value or its book value, called intrinsic value, which is Adicet Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adicet Bio's market value can be influenced by many factors that don't directly affect Adicet Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adicet Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adicet Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adicet Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.